Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04904276 · ClinicalTrials.gov registry record
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
A clinical trial, sponsored by Rigel Pharmaceuticals.
- Terminated
- Registry status
- 16
- Enrollment target
NCT04904276 is a clinical trial that was terminated before completion, run by Rigel Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT04904276 was terminated before completion, sponsored by Rigel Pharmaceuticals.
- TERMINATED
- Registry status
- 16 participants
- Enrollment target
Study Summary
Evaluate patient characteristics, treatment patterns, clinical outcomes and safety of fostamatinib as second-line therapy in real-world clinical practice, for the treatment of ITP in adult patients who have an insufficient response to prior therapy (steroids ± immunoglobulins).
Interventions
- DRUG Fostamatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2022-11-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04904276
The ClinicalTrials.gov registry entry for NCT04904276 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fostamatinib is the first listed.
NCT04904276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04904276 about?
NCT04904276 is a clinical study titled "Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy". Evaluate patient characteristics, treatment patterns, clinical outcomes and safety of fostamatinib as second-line therapy in real-world clinical practice, for the treatment of ITP in adult patients who have an insufficient response to prior therapy (steroids ± immunoglobulins).
What is the current status of trial NCT04904276?
This trial is currently terminated. The enrollment target is 16 participants. The study started on 2021-05-18. Estimated completion is 2022-11-17.
What interventions are being tested in trial NCT04904276?
The interventions under investigation include: Fostamatinib (DRUG).
Who is sponsoring clinical trial NCT04904276?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.